GSK_Annual_Report_2021

Notes to the Consolidated Financial Statements for the year ended March 31, 2021 (contd.) Annual Report 2020-21 207 Note 44 : Disclosures as required by Micro, Small and Medium Enterprises Development Act, 2006 are as under: ( ` in lakhs) As at March 31, 2021 As at March 31, 2020 (a) The principal amount and the interest due thereon remaining unpaid to suppliers (i) Principal 4,64.80 4,60.08 (ii) Interest due thereon 62.14 61.30 5,26.94 5,21.38 (b) (i) The delayed payments of principal amount paid beyond the appointed date during the entire accounting year 31,87.11 30,33.74 (ii) Interest actually paid under Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006 - - (c) (i) Normal Interest accrued during the year, for all the delayed payments, as per the agreed terms - - (ii) Normal Interest payable for the period of delay in making payment, as per the agreed terms - - (d) (i) Total Interest accrued during the year 0.84 53.90 (ii) Total Interest accrued during the year and remaining unpaid 0.84 53.90 The above information regarding Micro, Small and Medium enterprises has been determined to the extent such parties have been identified on the basis of information available with the Group. Note 45 : Tax expense (a) Amounts recognised in the Statement of Profit and Loss ( ` in lakhs) Particulars As at March 31, 2021 As at March 31, 2020 Current tax Current tax on profits for the year 184,30.17 235,31.46 Current tax on account of earlier years - 24,85.62 Total current tax expense 184,30.17 260,17.08 Deferred tax In respect of current year 8,04.93 (64,09.44) Adjustment to deferred tax attributable to change in income tax rate - 16,47.21 Total Deferred tax (benefit) / expense 8,04.93 (47,62.23) Total tax expense 192,35.10 212,54.85 (b) Amounts recognised in Other Comprehensive Income (OCI) Particulars Year ended March 31, 2021 Year ended March 31, 2020 Before tax Tax (expense) / benefit Net of tax Before tax Tax (expense) / benefit Net of tax Items that will not be reclassified to the Statement of Profit and Loss Remeasurements of the defined benefit plans (2,73.74) 68.90 (2,04.84) (4,56.06) 64.27 (3,91.79) (2,73.74) 68.90 (2,04.84) (4,56.06) 64.27 (3,91.79)